Figure 3

Gene-signature risk scores in relation to biological entities. Distributions of the subtypes (called by PAM50) stratified by ER status for individual gene signatures. Note that we used PAM50-classifications as proxy of proliferation. Luminal tumors dominate ER-positive group, while basal and Her2-enriched tumors drive the risk score higher in ER-negative group. In the ER-positive stratum, the risk assessment in most of the gene signatures is highly consistent with classification of luminal A and B tumors. Being more proliferative is known to distinguish luminal B tumors from luminal As. This indicates that the proliferation module, underlying many signatures, may drive the prognostication in ER-positive tumors.